Travere Therapeutic (TVTX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $18
Moomoo NewsAug 15 07:34 ET · Ratings
J.P. Morgan Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $20
Moomoo NewsAug 13 08:33 ET · Ratings
JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $20
BenzingaAug 13 08:29 ET · Ratings
Express News | Travere Therapeutics Inc : JP Morgan Raises Target Price to $20 From $19
ReutersAug 12 23:00 ET
Novartis Gets FDA Approval for Fabhalta in IgAN Patients
Seeking AlphaAug 7 16:57 ET
Travere Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswireAug 6 16:30 ET

Comments

Trytosaveabit

Aug 1 15:05

Hmm

$Travere Therapeutic (TVTX.US)$ Travere Therapeutics Q2 Operating Income USD -67.704 Million Vs. IBES Estimate USD -64.6 Million
Travere Therapeutics Q2 Product Sales USD 52.176 Million Vs. IBES Estimate USD 50.2 Million

Jaguar8

May 9 15:57

$Travere Therapeutic (TVTX.US)$
NEWS
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics to present data on FILSPARI at prestigious medical conferences, demonstrating the potential superiority of FILSPARI over existing treatments
Analyses show FILSPARI's ability to slow kidney function decline in patients with IgA nephropathy, offering a new approach to patient care
New 48-week findings from...

1

Trytosaveabit

Apr 24 04:27

Update

$Travere Therapeutic (TVTX.US)$ Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...

1

8

Meltyy

Apr 18 03:34

🎯 Ph 3 readouts in Q2 2024...

$Travere Therapeutic (TVTX.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...

19

Moomoo AI

Mar 15 09:07

The continuous decline in share price and revenue indicates unresolved challenges within the company. The company's future growth is uncertain and there are 4 warning signs in the investment analysis of Travere Therapeutics.

Further Weakness as Travere Therapeutics (NASDAQ:TVTX) Drops 14% This Week, Taking Three-year Losses to 72%

1

TVTX Travere Therapeutic

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target